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Abstract
Background:  ACTH overproduction within the pituitary gland or ectopically leads to
hypercortisolism. Here, we report the first case of Cushing' syndrome caused by an ectopic ACTH-
secreting neuroendocrine carcinoma of the mesentery. Moreover, diagnostic procedures and
pitfalls associated with ectopic ACTH-secreting tumors are demonstrated and discussed.
Case presentation: A 41 year-old man presented with clinical features and biochemical tests
suggestive of ectopic Cushing's syndrome. First, subtotal thyroidectomy was performed without
remission of hypercortisolism, because an octreotide scan showed increased activity in the left
thyroid gland and an ultrasound revealed nodules in both thyroid lobes one of which was
autonomous. In addition, the patient had a 3 mm hypoenhancing lesion of the neurohypophysis and
a 1 cm large adrenal tumor. Surgical removal of the pituitary lesion within the posterior lobe did
not improve hypercortisolism and we continued to treat the patient with metyrapone to block
cortisol production. At 18-months follow-up from initial presentation, we detected an ACTH-
producing neuroendocrine carcinoma of the mesentery by using a combination of octreotide scan,
computed tomography scan, and positron emission tomography. Intraoperatively, use of a gamma
probe after administration of radiolabeled 111In-pentetreotide helped identify the mesenteric
neuroendocrine tumor. After removal of this carcinoma, the patient improved clinically.
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Laboratory testing confirmed remission of hypercortisolism. An octreotide scan 7 months after
surgery showed normal results.
Conclusion: This case underscores the diagnostic challenge in identifying an ectopic ACTH-
producing tumor and the pluripotency of cells, in this case of mesenteric cells that can start
producing and secreting ACTH. It thereby helps elucidate the pathogenesis of neuroendocrine
tumors. This case also suggests that patients with ectopic Cushing's syndrome and an octreotide
scan positive in atypical locations may benefit from explorative radioguided surgery using 111In-
pentetreotide and a gamma probe.
Background
Endocrine tumors can develop from a variety of tissue
types and are often under- or misdiagnosed which under-
scores the difficulties to classify them. Ectopic ACTH over-
production not only leads to hypercortisolism but is also
associated with various diagnostic and therapeutic pitfalls
despite performing extensive diagnostic procedures.
Case presentation
In September 2003, a 41-year-old man presented with
unexplained progressive weight gain, facial plethora,
tremor, sweating, newly-diagnosed hypertension,
hypokalemia, and diabetes mellitus. Physical examina-
tion revealed a blood pressure of 170/110 mm Hg, pulse
of 88 bpm, thyroid enlargement, and cushingoid features
including striae, moon face, central obesity, and a buffalo
hump. Laboratory testing showed hyperthyroidism
(undetectable TSH, free T4 of 32 pmol/L (normal: 12–
22), free T3 of 9 pmol/L (normal: 3.95–6.80)) and
increased 24 h urinary free cortisol (7579 nmol per day,
normal range: 22–212). Thyroid ultrasound showed a
multinodular goiter. A Tc-99m-pertechnetate thyroid scan
revealed increased uptake in an area of the left thyroid
gland corresponding to an autonomous adenoma. Serum
calcitonin was within the normal range. Basal serum cor-
tisol and plasma ACTH were significantly elevated at 1307
nmol/l (normal range: 187–724) and 22.51 pmol/l
(1.98–11.4), respectively. After a 2-mg overnight dexame-
thasone suppression test, serum cortisol was still at 1132
nmol/l (normal, < 80). Midnight cortisol was elevated at
847 nmol/l. After an overnight 8-mg dexamethasone sup-
pression test, serum cortisol decreased by 38 % of basal
values suggesting ectopic ACTH-secretion (EAS). CRH
stimulated serum cortisol and plasma ACTH to less than
4 % of basal values. Inferior petrosal sinus sampling
(IPSS) did not show significant central-to-peripheral
ACTH gradients. Ectopic ACTH syndrome was diagnosed.
Computed tomography (CT) scans at first presentation
did not show pulmonary and/or abdominal tumors, how-
ever, both adrenals appeared enlarged with the left gland
showing a tumor of 1 cm size. A magnetic resonance
imaging (MRI) scan of the head demonstrated a small 3
mm hypointense and hypoenhancing lesion of the neuro-
hypophysis (Fig. 1). An 111In-pentetreotide scan showed
radiotracer enrichment in the left thyroid gland consistent
with the region of the autonomous adenoma and faint
focal octreotide enhancement in the abdomen which was
interpreted to be nonspecific because of lacking correla-
tion on CT scan and changing location of enhancement
between early and late scan (Fig. 2). Positron emission
tomography (PET) with 18F- fluorodeoxyglucose (FDG)
and colonoscopy showed normal results. Thyroid anti-
bodies were negative, supporting the scintigraphic finding
that hyperthyroidism in this patient was caused by an
autonomous adenoma. Given the scenario of EAS and an
octreoscan being reliably positive only in the left thyroid
gland, we decided to perform a left-sided hemithyroidec-
tomy and subtotal resection of the right gland after treat-
ment with methimazole, although basal calcitonin was
normal and pentagastrin stimulation could not be per-
formed because it was not available. Extensive pathologi-
cal workup of the thyroid specimen did not reveal an
ACTH-producing endocrine tumor but a 2 mm sized
benign nodule on the right side, and 2 benign nodules (1
T1-weighted gadolinium-enhanced MRI of the pituitary Figure 1
T1-weighted gadolinium-enhanced MRI of the pitui-
tary. A hypointense lesion of the neurohypophysis is indi-
cated.BMC Cancer 2006, 6:108 http://www.biomedcentral.com/1471-2407/6/108
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cm and 2 cm in diameter, respectively) within the left thy-
roid gland.
Whereas hyperthyroidism improved rapidly, hypercorti-
solism persisted. Because the patient had elevated liver
function tests, thereby limiting the use of ketoconazole,
we began metyrapone (2.5 g/d divided into 750 mg in the
morning and at noon, and 1 g in the evening to perform
medical adrenalectomy) combined with hydrocortisone
replacement (10 mg in the morning at at noon, and 5 mg
in the evening) to achieve normal 24 h urinary cortisol
values. Regular follow-up examinations at 3, 6, 9, and 12
months after initial presentation confirmed the pituitary
lesion within the posterior lobe, while CT scans of thorax
and abdomen remained negative except for the left-sided
adrenal tumor. 24 h urinary catecholamines including
fractionated metanephrines were negative. Over the fol-
lowing months, control of hypercortisolism by metyrap-
one became difficult and the question arose whether
bilateral adrenalectomy should be performed. Therefore,
we consulted a neuropathologist/pathologist (A.O.V.)
and neurosurgeon (E.H.O.) at the National Institutes of
Health whether they ever had seen an ACTH-producing
pituitary adenoma located in the posterior lobe (see ref.
1). Subsequently, transsphenoidal surgery was performed
to explore the pituitary lesion in our patient. Despite com-
plete removal of this lesion, hypercortisolism persisted
and metyrapone therapy was continued. Histological
workup of the removed pituitary tissue revealed normal
posterior pituitary. Postoperatively, diabetes insipidus
developed and persisted. An extensive re-evaluation was
performed 18 months after initial presentation. An octre-
oscan revealed tracer accumulation in projection of the
upper and middle part of the right abdomen (Fig. 2).
111In-pentetreotide scintigraphy Figure 2
111In-pentetreotide scintigraphy. Radiotracer accumulation in the left thyroid in 10/2003 (arrow). The mesenterial neu-
roendocrine tumor became clearly visible in 4/2005 (arrow).
10/2003             01/2004            04/2005
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Additional 18F-FDG PET showed increased glucose metab-
olism of this abdominal area. In accordance with these
findings, a 21 × 15 mm tumor mass was demonstrated on
CT and MRI scans in this region (Fig. 3). In retrospect, this
tumor could also be seen in earlier CT scans but had been
interpreted as normal intestine because of smaller size,
atypical location for an ACTH-producing tumor, and only
moderate uptake on octreotide scans. We decided to per-
form an explorative laparotomy. Before surgery, 111In-
pentetreotide was administered to support tumor locali-
zation during surgery with a gamma counter and facilitate
maximal tumor removal (Fig. 4). After the abdominal
wall had been opened, the neuroendocrine tumor was
instantly visible (Fig. 5). Because this lesion had been ini-
tially assumed to be metastatic tissue of a primary neu-
roendocrine tumor and a multifocal appearance of the
abdominal 111In-pentetreotide enhancement, the gamma
probe was used to detect further tumor tissue (Fig. 6). His-
topathological and immunohistochemical analyses of the
removed tissue revealed a well-differentiated neuroendo-
crine carcinoma of the mesentery with strong expression
of ACTH (Fig. 7). The tumor also strongly expressed NSE,
chromogranin A, and synaptophysin. The MIB-1 prolifer-
ation index was approximately 1 %. Immunohistochemi-
cal analyses for the expression of somatostatin receptors
type 1 to 5 were negative. All removed lymph nodes were
tumor-negative but also showed increased activity by the
gamma probe during surgery.
Follow-up at four weeks and at 4 (7) months after surgery
showed a normal 2 mg dexamethasone suppression test
and 24 h urinary cortisol levels. Plasma ACTH levels were
normal (4.9 and 5.2 pmol/L, normal: 1.8–12.8). NSE was
10.7 ng/ml (normal, < 13), chromogranin A and calci-
CT and MRI scans of the abdomen Figure 3
CT and MRI scans of the abdomen. In 4/2005, a mass (circle) is shown which has also been there in earlier scans but had 
been interpreted as normal intestine. Fat-saturated and T1-weighted MRI scanning after gadolinium shows a mass in the mesen-
tery outside the intestine.
04/2005 01/2004 09/2003
CT scans of the abdomen
MRI, T1, fat-saturated MRI, T1, before and after gadoliniumBMC Cancer 2006, 6:108 http://www.biomedcentral.com/1471-2407/6/108
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tonin were undetectable. In addition, the insulin require-
ment to treat the patient' s type 2 diabetes declined by
more than 50%. At 7 month follow-up, the patient had
regained strength and muscle mass, did not need further
potassium replacement, and felt fine. An octreoscan
showed normal results.
Discussion
We present for the first time a case of EAS caused by a neu-
roendocrine carcinoma of the mesentery. Among ectopic
ACTH-producing lesions, approximately 50% originate
from intrathoracic tumors, usually small cell carcinomas
[2-6]. Other well-described tumors of ectopic ACTH-pro-
duction include medullary thyroid carcinoma, pheochro-
mocytoma, as well as carcinomas of the thymus and
pancreas [2,7-11]. Except for the pancreas, other organs
and locations for ACTH-producing tumors in the abdo-
men, i.e. appendix, duodenum, ileum, colon, anal canal,
uterine cervix, and ovary are uncommon [12-20]. Endo-
crine tumors can develop from a variety of tissue types
and are often under- or misdiagnosed which underscores
the difficulties to classify them [21]. Endocrine tumors
may or may not produce and/or secrete hormones [22-
32]. Mesenchymal tumors such as solitary fibrous tumors
of the pleura, for instance, can lead to tumor hypoglyc-
emia through production and secretion of pro-IGF-II
[Fasshauer and Koch, unpublished observation; [33,34]].
This ability of tumor cells making hormones is not sur-
prising, if one considers the embryologic origin of tissues.
For instance, upon induction, ectoderm of the blastula
differentiates into mesodermal tissue such as chorda,
muscle, and fibrous tissue. Without induction, however,
ectoderm will differentiate into epidermis-like epithelium
[35]. Arita-Melzer et al. [24] reported a 76-yo man who
suffered from Cushing's syndrome caused by ectopic
ACTH production of a sacrococcygeal chordoma. In our
patient, we propose that cells of the mesentery became
malignant and started to produce ACTH ectopically.
Although all removed lymph nodes were negative for
tumor and the patient postoperatively became and
remained eucortisolemic at 7 month follow-up, there is
still a small chance that he harbors somewhere else a pri-
mary endocrine tumor producing ACTH that had metasta-
sized to the mesentery. Another atypical location for
primary endocrine tumors that had been controversially
discussed for a long time is the liver. Maire et al. [36] has
recently shown that this organ can harbor primary endo-
crine tumors, although the histogenesis of these tumors
remains unknown. One hypothesis claims that pluripo-
tent stem cells in the liver lead to primary endocrine
tumors, a theory that is supported by a study showing that
rat hepatic stem cells can differentiate into pancreatic
functional endocrine cells [37]. Another hypothesis
assumes that these liver tumor cells are of neuroectoder-
mal origin. In our patient, no liver lesions were seen. Pri-
mary endocrine tumors have also been reported in lymph
nodes [38]. In our patient, however, the removed tumor
tissue and lymph nodes did not demonstrate evidence for
lymph nodes as an origin of tumor growth.
Diagnosing EAS is often difficult [39,40]. None of the
dynamic biochemical tests achieves 100% accuracy,
although BIPSS almost always shows an absent central
gradient [41]. A recent report by Ilias and co-workers
emphasizes that 21 % and 26 % of patients with EAS have
false-positive responses to dexamethasone and/or CRH
[6]. In their hands, IPSS is the single best test for EAS that
correctly identified 66 out of 67 patients [6]. In our case,
Gamma probe used intraoperatively Figure 4
Gamma probe used intraoperatively.BMC Cancer 2006, 6:108 http://www.biomedcentral.com/1471-2407/6/108
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all three independent tests suggested EAS, since a) the
decline of serum cortisol was less than 50 % in the over-
night 8-mg dexamethasone suppression test as compared
to basal values, b) the increase in serum cortisol and
plasma ACTH was less than 20 % and 35 %, respectively,
after CRH stimulation, and c) IPSS demonstrated a less
than 2-fold central-to-peripheral ACTH gradient basal and
less than 3-fold gradient after CRH administration.
However, in the case presented, correct localization of
tumor causing the EAS had been difficult. The percentage
of tumors not identified despite extensive evaluation is
between 12% and 19% [5,6,42]. In our case, imaging
studies consisted of CT scans of chest, abdomen, and pel-
vis, an MRI scan of the pituitary, octreotide scans, and 18F-
FDG PET at initial presentation and during follow-up.
Except for PET, these tests are commonly used to locate
the cause of EAS [2,39,43-47]. Furthermore, octreotide
has been suggested not only as a diagnostic tool but also
as second-line therapy in some cases of EAS [48,49]. PET
is a second-line diagnostic procedure when CT scan, MRI,
and octreotide scan do not locate the cause of EAS [45]. In
the case presented, only the octreotide scan and the MRI
of the pituitary had yielded pathological results at first
presentation. Since EAS has been described in medullary
thyroid carcinoma and the patient had multinodular
goiter in association with hyperthyroidism, subtotal thy-
roidectomy was performed with the intention to exclude
medullary thyroid carcinoma and resect the proven
autonomous adenoma simultaneously in the face of a
normal basal calcitonin and lacking pentagastrin stimu-
lated calcitonin [8,10]. However, this surgical procedure
did not improve EAS. This result supports recent findings
by Becker and co-workers that false-positive octreotide
scans occur in endemic goiter with or without thyroid
autonomy [50]. Furthermore, it confirms recent reports
indicating that a positive octreotide scan alone may not be
sufficient to locate EAS [51]. In our patient, the octreotide
scan was also weakly positive in an abdominal area not
very typical for an ACTH-producing endocrine tumor that
later on, however, proved to be the cause for EAS. Simi-
larly, an 111In-pentetreotide scan provided the decisive
clue for locating a malignant ACTH-producing tumor of
the ileum in a patient reported by Segu et al. [15]. This
suggests that patients with EAS and a positive octreoscan
in locations atypical for an ACTH-producing tumor may
benefit from explorative surgery using 111In-pentetreotide
and a gamma probe.
Complicating the management of our patient with EAS
and clearcut negative IPSS, a small lesion of the neurohy-
pophysis was demonstrated at first presentation and dur-
ing 1-year follow-up. False-negative results of IPPS in
patients who do have an ACTH-producing pituitary tumor
are reported to occur in up to 13% (7/127) [52]. Given the
increasingly difficult to control hypercortisolemia, the
low risk of transsphenoidal surgery, and the recent find-
ings of clinical researchers at the National Institutes of
Health, where surgical removal of ACTHomas confined to
the neurohypophysis resulted in remission of hypercorti-
solism in 12 patients [1], we decided to proceed with an
exploration of the pituitary. However, in our case removal
of the posterior lobe pituitary lesion did not result in
remission of hypercortisolemia. These results re-empha-
size the notion that a single positive imaging study may
represent a falsely positive result, while more than one
positive study in the same region may confirm a true
ACTH-secreting lesion [2,6]. It also underscores that in
patients with Cushing's syndrome, dynamic biochemical
Macroscopic image of the tumor and removed lymph nodes Figure 6
Macroscopic image of the tumor and removed lymph nodes.
Intraoperative situs Figure 5
Intraoperative situs. A brown tumor mass is visible within 
the yellow mesentery.BMC Cancer 2006, 6:108 http://www.biomedcentral.com/1471-2407/6/108
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testing is the most important step in establishing the diag-
nosis. Because our patient with EAS also had a left sided
adrenal tumor in the setting of bilaterally enlarged adre-
nal glands, we measured 24 h urinary catecholamines
including metanephrines to exclude an ACTH-producing
pheochromocytoma which can occur in up to 25% of
patients with EAS. In a recent study, 3 of 28 patients with
ACTH-dependent Cushing's syndrome had focal adrenal
nodules [53]. Although non-catecholamine secreting phe-
ochromocytomas have been described [9,54], this is
unlikely in our patient who had remission of hypercorti-
solism and ACTH production after the mesenterial tumor
had been removed.
At 18-months after first presentation, another extensive
diagnostic procedure was performed including CT scans
of chest, abdomen, and pelvis, MRI head, octreotide scan,
and 18F-FDG PET. Here, tracer accumulation in projection
of the upper and middle part of the right abdomen was
detectable in the octreotide scan and PET, for the first time
corresponding to a 21 × 15 mm and 26 × 15 mm tumor
mass on CT and MRI scans, respectively. These results sup-
port the view that regular follow-up of occult EAS may
result in localization of ACTH production at later time
points due to tumor growth [2,6]. Furthermore, we could
show that application of 111In-pentetreotide within hours
before surgery facilitates localization of the tumor during
surgery by use of radiolabeled 111In-pentetreotide and a
gamma probe similar to recent reports [55,56].
To further elucidate whether patients with neuroendo-
crine tumors that are (supposedly) completely resected,
may benefit from adjuvant therapy including somatosta-
tin analogs, we performed a MIB-1 proliferation index of
the tumor in our patient and immunohistochemical anal-
yses of somatostatin receptor expression [57,58]. We
Images of histopathological Hematoxylin and Eosin stains and immunohistochemical ACTH expression Figure 7
Images of histopathological Hematoxylin and Eosin stains and immunohistochemical ACTH expression.
H & E
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found all 5 somatostatin receptors negative using immu-
nohistochemistry [59,60]. Especially the negative results
for somatostatin receptor type 2 stand in contrast to our
results on the octreoscans, although the tumor exceeded a
size of 5 mm which is usually regarded as the detection
limit for an octreoscan. These results may indicate that
this ACTH-producing neuroendocrine tumor is very heter-
ogeneous and/or somatostatin receptors were downregu-
lated/saturated by intraoperative exposure to high doses
of 111In-pentetreotide. Unfortunately, we were not able to
assess mRNA for somatostatin receptor expression.
Conclusion
We report for the first time a patient with EAS due to a
neuroendocrine carcinoma of the mesentery. This case
not only may help elucidate the pathogenesis of (ACTH-
producing) endocrine tumors, but also illustrates diag-
nostic pitfalls in the management of patients with EAS,
and suggests that patients with EAS and an octreoscan
positive in atypical locations may benefit from explorative
radioguided surgery using a gamma probe.
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